Atezolizumab Hepatocellular Carcinoma Trial Reaches Primary Completion

The IMbrave152 study (NCT05904886), investigating atezolizumab and bevacizumab, with or without tiragolumab, for participants with untreated locally advanced or metastatic Hepatocellular Carcinoma, reached its primary completion on 2025-05-08. This Phase 3 trial is evaluating combination therapies as a first-line treatment option.

Background

The IMbrave152 study aims to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab. This combination is being explored as a first-line treatment for participants diagnosed with unresectable, locally advanced or metastatic Hepatocellular Carcinoma (HCC).

Trial design

The IMbrave152 study (NCT05904886) is a Phase 3 trial that enrolled 687 participants. The study investigates atezolizumab and bevacizumab, with or without tiragolumab, in individuals with untreated locally advanced or metastatic Hepatocellular Carcinoma. An amendment to the study protocol recommended that participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm discontinue tiragolumab treatment, unless the investigator determines that the benefit outweighs the risk.

What this means

The primary completion of the IMbrave152 trial signifies that the main data collection for the study's primary endpoint has concluded. This milestone is a critical step towards the eventual release of results, which will provide important insights into the potential role of tiragolumab in combination with atezolizumab and bevacizumab for first-line treatment of advanced Hepatocellular Carcinoma. The protocol amendment regarding tiragolumab discontinuation suggests that safety or preliminary efficacy data may have influenced the study's ongoing conduct, and further details will be important for clinicians and researchers.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The primary completion date for study NCT05904886, titled "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)," was posted on 2025-05-08 on clinicaltrials.gov.